Answers are grounded in this paper and cite their sources.
Diabetic kidney disease (DKD) is a major microvascular complication of diabetes. Although the emergence of new therapies such as SGLT2 inhibitors, GLP-1 receptor agonists, aldosterone receptor antagonists, and endothelin receptor antagonists (ERAs) has expanded the therapeutic options for DKD, these therapies remain insufficient to meet the urgent clinical needs of contemporary society. Recent studies indicate that the pathogenesis of DKD involves multiple signaling pathways and drug targets. DKD is closely linked to the dysregulation of glucose, lipid, and amino acid metabolism. Compared to synthetic drugs, natural products offer advantages such as broader biological activities, favorable drug-like potential, multi-target mechanisms of action, enhanced safety and tolerability profiles, as well as abundant and renewable sources. Over the past two decades, natural products have demonstrated considerable potential in preclinical DKD studies (triptolide, quercetin, berberine, baicalin, resveratrol, proanthocyanidin B2), and various natural compounds are now considered integral components of comprehensive DKD management strategies, despite their disadvantages of poor solubility and low bioavailability. This review focuses on the cellular and molecular mechanisms through which natural products alleviate DKD by targeting metabolic disorders, summarizes the contributions of nanodelivery systems in improving the bioavailability of natural products, and presents related challenges in clinical translation, aiming to provide new insights for DKD treatment.
No takes yet. Share an insight, caveat, or question.
Fu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: